The Cooper Companies, Inc. (NASDAQ:COO) Given Consensus Rating of “Moderate Buy” by Analysts

The Cooper Companies, Inc. (NASDAQ:COO) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are currently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $100.38.

A number of analysts have recently issued reports on the stock. Robert W. Baird reduced their price objective on shares of Cooper Companies from $107.00 to $97.00 and set an “outperform” rating for the company in a research note on Friday, May 30th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Thursday, May 22nd. Wells Fargo & Company reduced their price objective on shares of Cooper Companies from $118.00 to $93.00 and set an “overweight” rating for the company in a research note on Friday, May 30th. Citigroup reduced their price objective on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Finally, BNP Paribas raised shares of Cooper Companies to a “hold” rating in a research note on Thursday, March 13th.

Institutional Investors Weigh In On Cooper Companies

Several institutional investors have recently made changes to their positions in the company. Covestor Ltd lifted its holdings in shares of Cooper Companies by 35.5% in the 4th quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after acquiring an additional 120 shares during the last quarter. Shell Asset Management Co. lifted its holdings in Cooper Companies by 15.5% during the 4th quarter. Shell Asset Management Co. now owns 946 shares of the medical device company’s stock valued at $87,000 after buying an additional 127 shares in the last quarter. UMB Bank n.a. lifted its holdings in Cooper Companies by 16.7% during the 1st quarter. UMB Bank n.a. now owns 902 shares of the medical device company’s stock valued at $76,000 after buying an additional 129 shares in the last quarter. Torray Investment Partners LLC lifted its holdings in Cooper Companies by 0.8% during the 4th quarter. Torray Investment Partners LLC now owns 16,190 shares of the medical device company’s stock valued at $1,488,000 after buying an additional 132 shares in the last quarter. Finally, Horizon Investments LLC lifted its holdings in Cooper Companies by 5.0% during the 1st quarter. Horizon Investments LLC now owns 2,859 shares of the medical device company’s stock valued at $241,000 after buying an additional 136 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Stock Up 1.6%

COO opened at $72.33 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. Cooper Companies has a 1-year low of $65.00 and a 1-year high of $112.38. The company has a market capitalization of $14.46 billion, a PE ratio of 37.09, a PEG ratio of 2.25 and a beta of 0.98. The firm’s 50 day simple moving average is $78.35 and its two-hundred day simple moving average is $87.31.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, May 29th. The medical device company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.03. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $995.12 million. During the same period last year, the firm earned $0.85 earnings per share. The company’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, equities analysts forecast that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.